Friday, November 22
BAKU: Nearly nine hours after the presidency of the UN climate talks was officially handed over to Azerbaijan, an agenda for the COP29 was adopted.The holdup was on account of divergence of views on two major issues. The first related to the way forward on the dialogue on the implementation of the outcomes of the global stocktake. The second was on a proposal submitted by China on behalf of the advanced developing countries quartet BASIC (Brazil, South Africa, India and China) on "climate change-related unilateral trade restrictive measures", simply put, the European Union's carbon border adjustment mechanism (CBAM).The dispute on the dialogue on the implementation of the outcomes of the global stocktake was about which track should house the discussions. At its core, the dispute is about
Shares of agrochemicals manufacturer UPL on Tuesday rose 5.6% to their day’s high of Rs 552.70 on the BSE trade after the company reported a net loss of Rs 443 crore for the second quarter of FY25, widening over 2.3 times from the year-ago period.The company reported a revenue of Rs 11,090 crore for the September quarter, compared to Rs 10,170 crore during the year-ago period. Revenue growth during the quarter was driven by a 16% year-on-year growth in volumes, and a 7% drop in prices and near-flat forex rates.Brokerage Phillip Capital noted that UPL reported strong volume expansion with an expected price decline in the second quarter, however, there are signs of revival in key markets which provide hope of normalcy in business from the second half of FY25 onwards. UPL has been facing is
Shares of Sagility India surged 9.6% to an intraday high of Rs 32.90 on the BSE after listing on the bourses on Tuesday. The stock debuted on the BSE at Rs 31.06, a premium of 3.5% over its upper price band of Rs 30.The stock opened at the same price on the NSE as well.Sagility India shares opened slightly above the market expectation of merely Rs 0.3 per share.The company made a decent debut on the stock market and the IPO received a moderate subscription of 3.2 times. The listing performance is considered positive given the company's specific focus on the US healthcare market, which is subject to various regulatory and economic factors.“Investors should remain cautious. The company's reliance on a single market and the potential impact of US policy changes could pose risks. Additionall
